View Older Stories View More Recent Stories

Nov 21, 2022 07:00AM Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
Nov 9, 2022 07:00AM Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Nov 7, 2022 07:00AM Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
Oct 31, 2022 07:00AM Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
Sep 12, 2022 05:22AM Concert Pharma (CNCE) Reports Presentation of CTP-543 THRIVE-AA1 Phase 3 Data
Sep 10, 2022 05:30AM Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
Sep 6, 2022 07:00AM Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Aug 22, 2022 07:10AM Concert Pharma (CNCE) to Present CTP-543 THRIVE-AA1 Phase 3 Trial Results at EADV Congress
Aug 22, 2022 07:05AM Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
Aug 22, 2022 07:00AM Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
Aug 4, 2022 07:00AM Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
Aug 1, 2022 07:00AM Concert Pharma (CNCE) Reports Positive Topline Results for Second CTP‑543 Phase 3 Study
Aug 1, 2022 07:00AM Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
Jul 29, 2022 07:00AM Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
Jun 9, 2022 07:00AM Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
Jun 7, 2022 07:01AM Concert Pharma (CNCE) Reports Publication of Phase 2 Dose‑Ranging Trial Results of CTP‑543
Jun 7, 2022 07:00AM Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
May 23, 2022 07:00AM Concert Pharma (CNCE) Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial
May 23, 2022 07:00AM Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
May 5, 2022 07:00AM Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
Apr 28, 2022 07:00AM Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
Mar 3, 2022 06:00AM Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
Feb 24, 2022 07:00AM Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
Jan 4, 2022 07:00AM Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Jan 3, 2022 07:00AM Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
Nov 11, 2021 07:00AM Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
Nov 9, 2021 07:00AM Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
Nov 2, 2021 07:00AM Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
Oct 25, 2021 07:00AM Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Sep 3, 2021 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 5, 2021 07:00AM Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
Jul 29, 2021 07:00AM Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021
Jul 1, 2021 07:12AM Concert Pharma (CNCE) Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit
Jul 1, 2021 07:00AM Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit
May 27, 2021 07:00AM Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
May 26, 2021 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
May 17, 2021 04:10PM Concert Pharma (CNCE) Announces Sale of VX-561 Milestones to Vertex (VRTX) for $32 Million
May 17, 2021 04:01PM Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million
May 4, 2021 07:00AM Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
Apr 27, 2021 07:00AM Concert Pharmaceuticals to Report First Quarter 2021 Results on May 4, 2021
Mar 2, 2021 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 25, 2021 07:00AM Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
Feb 18, 2021 07:00AM Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021
Feb 1, 2021 07:01AM Concert Pharma (CNCE) CTP-692 Phase 2 Trial in Patients with Schizophrenia Did Bot Meet Primary Endpoint
Feb 1, 2021 07:00AM Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia
Nov 9, 2020 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 5, 2020 06:00AM Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
Nov 3, 2020 07:21AM Concert Pharma (CNCE) Begins THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Nov 3, 2020 07:00AM Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Oct 29, 2020 10:00AM Concert Pharma (CNCE) Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
View More Recent Stories View Older Stories